Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect

Human Pathology

Volumn 44, Issue 7, 2013, Pages 1286-1292

  Munfus Mccray, Delicia ^a   Cui, Min ^a   Zhang, Zhen ^a   Gabrielson, Edward ^a   Askin, Frederic ^a   Li, Qing Kay ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

EGFR mutation; KRAS mutations; Lung adenocarcinoma; Primary and metastatic non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; EXON; FEMALE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATION RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84879222233     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.10.016     Document Type: Article

References (33)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, and T. Mitsudomi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 2004 8919 8923
3. J.G. Paez, P.A. Jänne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
4. W. Pao, V. Miller, and M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311
5. T. Mitsudomi, and Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 2007 1817 1824
6. R. Beroukhim, C.H. Mermel, and D. Porter The landscape of somatic copy-number alteration across human cancers Nature 463 2010 899 905
7. N. Fujimoto, M. Wislez, and J. Zhang High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor Cancer Res 65 2005 11478 11485
8. D.A. Eberhard, B.E. Johnson, and L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
9. T. Mitsudomi, S.M. Steinberg, and H.K. Oie ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent Cancer Res 51 1991 4999 5002
10. H. Linardou, I.J. Dahabreh, and D. Kanaloupiti Assessment of somatic KRAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972
11. W. Pao, T.Y. Wang, and G.J. Riely KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
12. M.-S. Tsao, A. Sakurada, and J.C. Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
13. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
14. N. Thatcher, A. Chang, and P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
15. F.R. Hirsch, M. Varella-Garcia, and P.A. Bunn Jr. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 2006 5034 5042
16. D. Munfus-McCray, S. Harada, and C. Adams EGFR and KRAS mutations in metastatic lung adenocarcinomas Hum Pathol 42 2011 1447 1453
17. A. Kalikaki, A. Koutsopoulos, and M. Trypaki Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC Br J Cancer 99 2008 923 929
18. G. Badalian, T. Barbai, E. Raso, K. Derecskei, M. Szendroi, and J. Timar Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status Pathol Oncol Res 13 2007 99 104
19. N. Motoi, J. Szoke, and G.J. Riely Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis Am J Surg Pathol 32 2008 810 827
20. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, and A. Trotti AJCC cancer staging manual 7th ed 2010 Springer New York
21. A.C. Tsiatis, A. Norris-Kirby, and R.G. Rich Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations. Diagnostic and clinical implications J Mol Diagn 12 2010 425 432
22. W. Pao, V.A. Miller, and K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
23. T. Kosaka, Y. Yatabe, and H. Endoh Analysis of epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer and acquired resistance to gefitinib Clin Cancer Res 12 2006 5764 5769
24. K. Suda, K. Tomizawa, and H. Osada Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation Lung Cancer 76 2012 292 299
25. A. De Luca, and N. Normanno Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer Curr Drug Targets 11 2010 851 864 [Review]
26. H. Uramoto, H. Shimokawa, T. Hanagiri, M. Kuwano, and M. Ono Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma Lung Cancer 73 2011 361 365
27. K. Suda, K. Tomizawa, and M. Fujii Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib J Thorac Oncol 6 2011 1152 1161
28. Q.K. Li, E. Gabrielson, and H. Zhang Application of glycoproteomics for the discovery of biomarkers in lung cancer Proteomics: Clinical App. 5-6 2012 244 256
29. F. Janku, I. Garrido-Laguna, L.B. Petruzelka, D.J. Stewart, and R. Kurzrock Novel therapeutic targets in non-small cell lung cancer J Thorac Oncol 6 2011 1601 1612 [Review]
30. J.R. Dobosy, J.L. Roberts, V.X. Fu, and D.F. Jarrard The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia J Urol 177 2007 822 831
31. C. Jerónimo, P.J. Bastian, and A. Bjartell Epigenetics in prostate cancer: biologic and clinical relevance Eur Urol 60 2011 753 766
32. Q.K. Li, E. Gabrielson, F. Askin, D.W. Chan, and H. Zhang Glycoproteomics using fluid based specimens in the discovery of lung cancer protein biomarkers. Promise and challenge Proteomics Clinical App 2012 In press
33. C. Bozzetti, F.V. Negri, and C. Azzoni Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples Diagn Cytopathol 2012 10.1002/dc.22905 [Epub ahead of print]